A federal judge has certified a class of third-party purchasers who allege that GlaxoSmithKline filed “sham” citizen petitions with the Food and Drug Administration that kept generic versions of its nasal spray called Flonase off the market for two years.
U.S. District Judge Anita Brody of the Eastern District of Pennsylvania narrowed the class to only those who purchased the generic equivalent after it became available and to those who purchased Flonase in one of four states.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
